The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Shares of Sarepta Therapeutics SRPT surged more than 30% in after-market trading yesterday after the company announced a ...

Sarepta Therapeutics (NASDAQ:SRPT) said a third patient has died from acute liver failure after receiving one of its gene therapies, intensifying scrutiny over the safety of its treatments, Bloomberg ...

Shares of Sarepta Therapeutics declined 16.5% to $18.32 in premarket trading on Friday after a Bloomberg report that a patient enrolled in an early-stage study of one of the company's gene therapies ...

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

Shares of drug developer Sarepta Therapeutics surged more than 20% in morning trading, rising after the late-Wednesday news ...

Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to ...

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the best low priced pharma stocks to buy now. Towards the end of June, ...

Biopharma stock Sarepta Therapeutics Inc (NASDAQ:SRPT) is soaring today, up 20.6% at $22.17 at last glance. The biopharmaceutical company announced a strategic restructuring plan, laying off about 500 ...

The gene-therapy company is restructuring, laying off 36% of its workforce and making changes to its executive team.

Sarepta Therapeutics will cut 500 jobs and add a serious warning on the label of its muscle-disorder gene therapy Elevidys, the drugmaker said on Wednesday, following the recent deaths of two patients ...

After the market close on Wednesday, Sarepta Therapeutics introduced a strategic restructuring plan that involves focusing on high-value, high-impact programs and supporting long-term financials.